Volition© 2021 March 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anti ...

VolitionRx Limited (NYSE:VNRX) Q4 2020 Results Conference Call March 23, 2021 8:00 AM ET Company Participants Scott Powell - Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Dr. Jake Micallef - Chief Scientific Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Jason McCarthy - Maxim Group Nathan Weinstein - Agesi Capital Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen, and thank you for standin ...

Volition© 2021 March 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] For the Fiscal Year Ended December 31, 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] For the transition period from _____ to ______ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor ...

VolitionRx Ltd. (NYSE:VNRX) Q3 2020 Earnings Conference Call November 13, 2020 8:30 AM ET Company Participants Scott Powell - EVP, IR Cameron Reynolds - President and CEO David Vanston - CFO Jason Terrell - Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Kyle Mikson - Cantor Fitzgerald Bruce Jackson - Benchmark Company Jason Kolbert - Dawson James Steven Ralston - Zacks Investment Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to ...

Volition© 2020 Corporate Presentation November 2020 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "a ...

[PART I - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20FINANCIAL%20STATEMENTS%20(UNAUDITED)) Presents unaudited financial statements highlighting a 'going concern' issue, recent equity raises, and significant subsequent events Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | September 30, 2020 | December 31, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $20,927,729 | $16,966,168 | | Total Current Assets | $22,164,523 | $17,556,279 | | Total Assets | $26,087,571 | $21,291,292 | | **Liabilities & Equity** | | | | Total Current Liabilities | $4,317,909 | $3,859,874 | | Total Liabilities | $7,126,160 | $7,092,726 | | Total Stockholders' Equity | $18,961,411 | $14,198,566 | Condensed Consolidated Statements of Operations Highlights (Unaudited) | Account | Nine Months ended Sep 30, 2020 | Nine Months ended Sep 30, 2019 | | :--- | :--- | :--- | | Total Revenues | $6,313 | $17,096 | | Research and development | $10,567,988 | $7,596,097 | | Total Operating Expenses | $15,595,009 | $12,335,037 | | Net Loss | ($15,238,380) | ($12,541,749) | | Net Loss Per Share | ($0.34) | ($0.33) | - The company has incurred losses of **$105.0 million** since inception and has negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern[42](index=42&type=chunk) - In May 2020, the company completed a public offering, issuing approximately 5 million shares for aggregate gross proceeds of **$13.8 million**, resulting in net proceeds of **$12.7 million**[61](index=61&type=chunk) - Subsequent to the quarter end, the company raised approximately **$471,600** under its equity distribution agreement, borrowed **$973,000**, and entered a new **$25 million** "at the market" offering program[122](index=122&type=chunk)[123](index=123&type=chunk)[129](index=129&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20MANAGEMENT'S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management analyzes financial results, noting increased R&D spending and a higher net loss, while highlighting liquidity from equity offerings and a going concern warning [Company Overview, Developments, and Liquidity](index=25&type=section&id=Company%20Overview%2C%20Developments%2C%20and%20Liquidity) Details the company's epigenetics platform, cash position of $20.9 million, operating cash burn, and the auditors' going concern warning - The company applies its Nucleosomics platform to develop simple, cost-effective blood tests to help diagnose a range of cancers and other diseases[136](index=136&type=chunk) - As of September 30, 2020, the company held cash and cash equivalents of approximately **$20.9 million**[140](index=140&type=chunk) - Net cash used in operating activities increased to **$13.7 million** for the nine months ended September 30, 2020, from $10.1 million in the prior-year period, mainly due to higher R&D expenditures[141](index=141&type=chunk) - Net cash provided by financing activities was **$18.5 million** for the nine months ended September 30, 2020, primarily from a public offering and an Equity Distribution Agreement[145](index=145&type=chunk) - Auditors issued a **going concern warning** in their report for the year ended December 31, 2019, due to the company's history of not attaining profitable operations[150](index=150&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Compares quarterly and nine-month results, showing a widening net loss driven by a significant increase in R&D expenses Comparison of Operations - Three Months Ended September 30 | Metric | 2020 | 2019 | Change | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Revenues | $575 | $17,096 | ($16,521) | (97%) | | R&D Expenses | $3,180,177 | $2,642,610 | $537,567 | 20% | | G&A Expenses | $1,080,308 | $1,354,992 | ($274,684) | (20%) | | Net Loss | ($4,335,948) | ($4,180,805) | $155,143 | 4% | Comparison of Operations - Nine Months Ended September 30 | Metric | 2020 | 2019 | Change | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Revenues | $6,313 | $17,096 | ($10,783) | (63%) | | R&D Expenses | $10,567,988 | $7,596,097 | $2,971,891 | 39% | | G&A Expenses | $4,292,666 | $4,020,893 | $271,773 | 7% | | Net Loss | ($15,238,380) | ($12,541,749) | $2,696,631 | 22% | - The increase in R&D expenses for the nine-month period was primarily related to higher antibody costs, sample costs, laboratory expenses, and personnel expenses[167](index=167&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company is exempt from market risk disclosures as a smaller reporting company - The company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information under this item[181](index=181&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20CONTROLS%20AND%20PROCEDURES) Management concludes disclosure controls were ineffective due to material weaknesses in financial reporting, with a remediation plan underway - Management concluded that the company's disclosure controls and procedures were **not effective** as of September 30, 2020[183](index=183&type=chunk) - **Material weaknesses** were identified due to insufficient segregation of duties in Finance, inadequate oversight in Information Technology, and a lack of monitoring controls for complex transactions[189](index=189&type=chunk) - The company is implementing a remediation plan that includes selecting a new financial reporting system to automate processes and strengthen controls[185](index=185&type=chunk) [PART II - OTHER INFORMATION](index=33&type=section&id=PART%20II%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20LEGAL%20PROCEEDINGS) The company is not aware of any material existing or pending legal proceedings - The company knows of **no material, existing or pending legal proceedings** against it[192](index=192&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20RISK%20FACTORS) No material changes to risk factors have occurred since previous filings - There have been **no material changes** in the company's assessment of risk factors affecting its business since those presented in its Annual Report and the Q1 2020 Form 10-Q[193](index=193&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) No unregistered sales of equity securities or use of proceeds were reported for the period - None[194](index=194&type=chunk) [Item 3. Defaults Upon Senior Securities](index=33&type=section&id=Item%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES) No defaults upon senior securities were reported - None[195](index=195&type=chunk) [Item 4. Mine Safety Disclosures](index=33&type=section&id=Item%204.%20MINE%20SAFETY%20DISCLOSURES) Mine safety disclosures are not applicable to the company's operations - Not applicable[196](index=196&type=chunk) [Item 5. Other Information](index=33&type=section&id=Item%205.%20OTHER%20INFORMATION) Discloses significant subsequent events, including a new CEO consulting agreement and a $25 million 'at the market' offering program - On November 10, 2020, the company entered into a new consulting services agreement for its Group Chief Executive Officer, Cameron Reynolds, with a monthly fee of **$35,650**[197](index=197&type=chunk) - On November 12, 2020, the company entered into an Equity Distribution Agreement to sell up to **$25,000,000** of its common stock through an "at the market" offering program[199](index=199&type=chunk) [Item 6. Exhibits](index=35&type=section&id=Item%206.%20EXHIBITS) Lists all exhibits filed with the report, including key agreements and officer certifications - The report includes several exhibits, notably the Equity Distribution Agreement (1.1), a legal opinion (5.1), a consulting services agreement (10.1), and certifications from the CEO and CFO (31.1, 31.2, 32.1)[202](index=202&type=chunk)

Financial Data and Key Metrics Changes - The company closed the second quarter of 2020 with $21.3 million in cash and cash equivalents, up from $12 million at the end of the previous quarter [12] - During the second quarter, the company raised $13.8 million in gross proceeds from an underwritten public offering, and approximately $1.6 million through its At The Market (ATM) offering program [12][13] - The monthly burn rate has increased to approximately $1.6 million to $1.7 million as the company approaches commercialization [17] Business Line Data and Key Metrics Changes - The company has developed 13 assays as of June 30, meeting its target of 12 assays, with plans to reach a total of 20 by the end of the year [32] - The company has manufactured its first recombinant nucleosomes in-house, with plans for additional production [33] Market Data and Key Metrics Changes - The company has been added to the Russell 3000 and Russell Microcap Indexes, marking a significant step forward [16] Company Strategy and Development Direction - The company aims to launch its first products later this year, focusing on the COVID-19 triage test and cancer diagnostics [7][52] - Plans to purchase a neighboring facility in Belgium to secure supply chains and reduce production costs [11][41] - The company is focused on developing a prognostic test for COVID-19, which could also be applicable for other respiratory viral outbreaks [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed pride in the team's adaptability during the pandemic and emphasized the importance of maintaining operations [7] - The company is optimistic about the potential of its Nu.Q platform in various applications, including COVID-19 and cancer diagnostics [23][50] - Management highlighted the ongoing challenges posed by the pandemic but remains committed to achieving key milestones [34][52] Other Important Information - The company is in discussions with a major U.S. contract research organization to conduct a large prospective prognostic COVID-19 study [26] - The company plans to launch a low-cost product that could be used in any laboratory worldwide [30] Q&A Session Summary Question: Can you provide more detail on the upcoming CE mark? - The CE mark is expected for a triage product related to blood cancers, specifically the H3.1 assay, which has shown excellent results [56][58] Question: How many assays are needed for a CE mark? - The H3.1 assay has shown impressive results, and while one assay is sufficient for CE marking, more assays typically improve accuracy [59][60] Question: What is the need for prognostic indicators in COVID-19? - Prognostic tools are essential for determining the severity of COVID-19 symptoms and guiding treatment decisions [61][62] Question: What is the status of the COVID-19 longitudinal studies? - The company has collected some longitudinal data and is working on additional studies in Europe and the U.S. [87][90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inc ...